In brief
Andrew von Eschenbach argues that decades of investment in cancer and molecular biology have given the world tools to fight COVID-19 quickly. He says the FDA is now the agency that must turn that knowledge into tests and treatments. His proposals are shared real-world data, working in parallel, repurposing existing drugs, adapting cancer immunotherapy, and closer global cooperation.
The episode moves from urgent practical steps to a personal and moral point. Vaccines will take time, so treatments and data sharing matter most in the short run. Von Eschenbach and Mike Milken both lost fathers to cancer. They frame that loss as a 'legacy' that should drive society to be better prepared for the next threat.
Questions
Why does Andrew von Eschenbach say the FDA is so important in the pandemic?
He says research knowledge only helps people once it is delivered as tests and therapies. The FDA must make sure those products reach people quickly while also being safe and effective.
What does it mean to use 'real-world data' instead of a clinical trial?
Von Eschenbach means collecting information from how patients are actually treated now, using electronic medical records with their permission. He says this can show when and for whom existing drugs work faster than long randomized trials.
How could cancer research help fight a virus like COVID-19?
Von Eschenbach says cancer research taught us how the immune system recognizes diseased cells. That same ability should work on virus-infected cells, and he cites FDA-approved trials using natural killer cells.
Which existing drugs does he mention, and are they proven to work?
He mentions hydroxychloroquine, used for malaria, rheumatoid arthritis and lupus, and an antibiotic he calls erythromycin. He does not claim they are proven. He says data is needed to learn when, how and for whom they work.
What does the 'legacy' he talks about refer to?
Both he and Mike Milken lost their fathers to cancer. They turned that loss into a lifelong effort to prevent others from suffering the same way, and von Eschenbach hopes the pandemic prompts the same response.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Andrew von Eschenbach, a former FDA commissioner, is a former director of the National Cancer Institute and is president of Samaritan Health Initiatives.
“He is also the former director of the National Cancer Institute and is currently president of Samaritan Health Initiatives.”
0:00:18 · Speaker 3 · Von Eschenbach · 2020
Mike Milken says he and Andrew von Eschenbach have devoted much of the past 50 years to accelerating medical research.
“Andy, you and I have devoted much of the last 50 years of our life to accelerating medical research.”
0:00:46 · Mike Milken · Medical research
Andrew von Eschenbach says modern cell-based methods could cut vaccine production from the normal year to 18 months down to six months or less.
“not take the normal year to 18 months, but to cut that immediately down to six months or less.”
0:05:23 · Andrew von Eschenbach · Vaccine production · 2020
Andrew von Eschenbach says monoclonal antibodies could be developed from antibodies made by people who have recovered from the coronavirus.
“develop monoclonal antibodies by finding people who have conquered the virus, have already made an antibody within their own system to destroy or fight off that virus.”
0:06:27 · Andrew von Eschenbach · Monoclonal antibodies · 2020
Andrew von Eschenbach says the FDA approved clinical trials using the body's immune system, including natural killer cells, against the coronavirus.
“FDA has approved clinical trials to use our own body's immune system, including using natural killer cells that are already in our body.”
0:08:11 · Andrew von Eschenbach · Immunotherapy · 2020
Andrew von Eschenbach says hydroxychloroquine was already used for malaria, rheumatoid arthritis and lupus before it was used against COVID-19.
“hydroxychloroquine, which was used for malaria and rheumatoid arthritis and lupus”
0:08:45 · Andrew von Eschenbach · Hydroxychloroquine · 2020
Andrew von Eschenbach says real-world patient data must be acquired, aggregated and analyzed to learn how off-the-shelf drugs work against COVID-19.
“we'll have to capitalize on the opportunity to acquire, aggregate, and analyze real-world data”
0:10:09 · Andrew von Eschenbach · Real-world data · 2020
Andrew von Eschenbach says existing electronic medical record systems should be used, with patient permission, to capture COVID-19 treatment data.
“We need to capitalize on the healthcare systems that are already in place based on an electronic medical record, recruit and utilize them with patient's permission to be able to get access to that data.”
0:11:03 · Andrew von Eschenbach · Medical records · 2020
Andrew von Eschenbach says spending hundreds of millions on a vaccine candidate that proves not to be the best would still be a worthwhile investment.
“It may very well be that we'll develop a vaccine and spend a considerable amount of money, hundreds of millions perhaps, and it may not be the absolute best vaccine in the long run.”
0:11:40 · Andrew von Eschenbach · Vaccine investment · 2020
Andrew von Eschenbach says that while he led the FDA, much production of drug ingredients, excipients and gelatin capsules took place outside the United States.
“the production of, for example, active pharmaceutical ingredients and excipients, even the gelatin that you find your medicines encapsulated in, and many other things were occurring and being developed outside the United States.”
0:13:54 · Andrew von Eschenbach · Global supply chain
Under Andrew von Eschenbach, the FDA created its 'Beyond Our Borders' program and placed personnel and offices in China, India, Europe, Central America and later the Middle East.
“we created FDA Beyond Our Borders and actually put FDA personnel and offices in China, in India, in Europe, in Central America, and eventually in the Middle East.”
0:14:35 · Andrew von Eschenbach · FDA Beyond Our Borders
Andrew von Eschenbach says Mike Milken advocated for dramatic funding increases at the National Cancer Institute and the National Institutes of Health.
“You not only advocated for dramatic increases in funding at the National Cancer Institute and the NIH”
0:07:02 · Andrew von Eschenbach · Research funding
Andrew von Eschenbach says Mike Milken pushed the academic and scientific community to collaborate and break down silos, helping create an era of molecular medicine.
“And what you did was force us to collaborate and cooperate, to break down silos.”
0:07:02 · Andrew von Eschenbach · Research collaboration · 1990s
Mike Milken says his father was dying of melanoma during the 1970s, when Milken was having enormous professional success.
“In the 1970s, I had enormous success, but I could never share my success with my father because he was dying of melanoma.”
0:16:08 · Mike Milken · Milken's father · 1970s
Mike Milken recalls an event on the steps of the U.S. Capitol honoring doctors and scientists who made dramatic changes in cancer research, where von Eschenbach spoke of his late father.
“as we stood on the steps of the Capitol, honoring the doctors, scientists that had made dramatic changes in cancer and cancer research”
0:16:40 · Mike Milken · Capitol event